Literature DB >> 9149283

Antigenicity and immunogenicity of multiple antigen peptides (MAP) containing P. vivax CS epitopes in Aotus monkeys.

S Herrera1, C De Plata, M González, B L Perlaza, F Bettens, G Corradin, M Arévalo-Herrera.   

Abstract

Using linear synthetic peptides corresponding to the Plasmodium vivax circumsporozoite (CS) protein of the common type, we have identified several T and B-cell epitopes recognized by human individuals. Three T-cell epitopes studied (p6) from the amino, (p11) from the central and (p25) from the carboxyl regions, were widely recognized by lymphocytes of immune donors. A series of six peptides, in addition to p11, representing the central repeat domain of the CS(p11-p17) protein were used in ELISA assays to map the B-cell epitopes of this region. P11 was the peptide most frequently recognized by sera containing antibodies to the homologous CS protein as determined by IFAT. The sequences corresponding to peptides p6, p11 and P25 as well as that representing a universal T-cell epitope derived from the tetanus toxin were used to assemble eight different Multiple Antigen Peptides (MAP). The immunogenicity of these MAP was analysed in Aotus monkeys. Groups of two animals were immunized with each MAP and both antibody response, T-lymphocyte proliferation and in vitro gamma-IFN production were evaluated. Two MAPs containing the same B-cell epitope and either a promiscuous CS-protein derived T-cell epitope (p25) or the tetanus toxin epitope (p-tt30) proved to be the most immunogenic and induced high levels of anti-peptide antibodies that recognized the native protein. Except for animals immunized with MAP VII, there was no correlation between antibody levels, lymphocyte proliferation or gamma-IFN production in vitro. The broad recognition of these epitopes by individuals which had been exposed to malaria, the capacity of these MAPs to induce antibodies, recognize the cognate protein, and in vitro gamma-IFN production encourages further analyses of the potential of these proteins as malaria vaccine candidates for human use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9149283     DOI: 10.1046/j.1365-3024.1997.d01-193.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  10 in total

Review 1.  Platform for Plasmodium vivax vaccine discovery and development.

Authors:  Sócrates Herrera Valencia; Diana Carolina Rodríguez; Diana Lucía Acero; Vanessa Ocampo; Myriam Arévalo-Herrera
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

2.  Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys.

Authors:  B L Perlaza; M Arévalo-Herrera; K Brahimi; G Quintero; J C Palomino; H Gras-Masse; A Tartar; P Druilhe; S Herrera
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

3.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

4.  High-throughput molecular diagnosis of circumsporozoite variants VK210 and VK247 detects complex Plasmodium vivax infections in malaria endemic populations in Papua New Guinea.

Authors:  Cara N Henry-Halldin; Daphne Sepe; Melinda Susapu; David T McNamara; Moses Bockarie; Christopher L King; Peter A Zimmerman
Journal:  Infect Genet Evol       Date:  2010-12-13       Impact factor: 3.342

5.  Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.

Authors:  Joanne M Lumsden; Sathit Pichyangkul; Utaiwan Srichairatanakul; Kosol Yongvanitchit; Amporn Limsalakpetch; Saule Nurmukhambetova; Jennifer Klein; Sylvie Bertholet; Thomas S Vedvick; Steven G Reed; Jetsumon Sattabongkot; Jason W Bennett; Mark E Polhemus; Christian F Ockenhouse; Randall F Howard; Anjali Yadava
Journal:  Infect Immun       Date:  2011-06-20       Impact factor: 3.441

6.  Humoral hyporesponsiveness to a conjugate contraceptive vaccine and its bypass by diverse carriers using permissible adjuvant.

Authors:  A Mandokhot; R Pal; S Nagpal; V S Chauhan; S Ahlawat; O Singh
Journal:  Clin Exp Immunol       Date:  2000-10       Impact factor: 4.330

7.  A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.

Authors:  Anjali Yadava; Jetsumon Sattabongkot; Michael A Washington; Lisa A Ware; Victoria Majam; Hong Zheng; Sanjai Kumar; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2006-12-11       Impact factor: 3.441

Review 8.  Progress towards the development of a P. vivax vaccine.

Authors:  Sai Lata De; Francis B Ntumngia; Justin Nicholas; John H Adams
Journal:  Expert Rev Vaccines       Date:  2021-03-04       Impact factor: 5.217

9.  Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region.

Authors:  Anjali Yadava; Cysha E Hall; JoAnn S Sullivan; Douglas Nace; Tyrone Williams; William E Collins; Christian F Ockenhouse; John W Barnwell
Journal:  PLoS Negl Trop Dis       Date:  2014-10-16

10.  Characterizing PvARP, a novel Plasmodium vivax antigen.

Authors:  Darwin A Moreno-Pérez; Ambar Saldarriaga; Manuel A Patarroyo
Journal:  Malar J       Date:  2013-05-20       Impact factor: 2.979

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.